

## Monoclonal Antibodies: Xolair – NASAL POLYPS

### Member Information

1. Last Name: \_\_\_\_\_ 2. First Name: \_\_\_\_\_  
3. Trillium ID #: \_\_\_\_\_ 4. Date of Birth: \_\_\_\_\_ 5. Gender: \_\_\_\_\_

### Prescriber Information

1. Prescriber Name: \_\_\_\_\_ 2. NPI #: \_\_\_\_\_  
3. Requestor Name (Nurse/Office Staff): \_\_\_\_\_  
4. Mailing Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_  
5. Phone #: \_\_\_\_\_ Ext. \_\_\_\_\_ Fax #: \_\_\_\_\_

### Drug Information

1. Drug Name: **Xolair** 2. Strength: \_\_\_\_\_ 3. Quantity per 30 Days: \_\_\_\_\_  
4. Length of Therapy (in Days):  up to 30 Days  60 Days  90 Days  120 Days  180 Days  365 Days

### Clinical Information

#### Nasal Polyyps: New Therapy

1. Is the member 18 years of age or older?  **Yes**  **No**
2. Does the member weigh between 30kg (66lbs) and 150kg (330lbs)?  **Yes**  **No**  
**Member's Weight:** \_\_\_\_\_
3. Does the member have an IgE level above 30IU/ml?  **Yes**  **No**  
**Please list level:** \_\_\_\_\_
4. Does the member have a diagnosis of Nasal Polyyps?  **Yes**  **No**
5. Has the member tried and failed monotherapy with nasal steroids?  **Yes**  **No**
6. Will the member continue to receive intranasal steroid concomitantly?  **Yes**  **No**

#### Nasal Polyyps- Continuation of Therapy (please answer questions 1-7)

7. Is the member receiving continued clinical benefit from baseline supported by medical records?  **Yes**  **No**  
**\*If yes, please attach medical records\***

Signature of Prescriber: \_\_\_\_\_ Date: \_\_\_\_\_

**(Prescriber Signature Mandatory)**

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.